Akari Therapeutics names David Horn Solomon as CEO

21 August 2017

UK-registered Akari Therapeutics (Nasdaq: AKTX) has appointed Dr David Horn Solomon as the company’s new chief executive, effective August 28, 2017.

“I am very pleased that David will be joining Akari and that we have been successful in attracting a person of his calibre and with over 20 years of leadership experience in the biotechnology industry,” said Ray Prudo, executive chairman of Akari. “David has a strong track record of leading Phase II-stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialized by Sanofi.”

Dr Horn Solomon was the CEO of Zealand Pharma from 2008 to 2015. Under his leadership the company went public on Nasdaq OMX in Copenhagen and its lead product, Adlixin, a GLP-1 receptor agonist for the treatment of type 2 diabetes, was approved in the USA and globally and is now marketed by Sanofi. Dr Horn Solomon was also the CEO of Bionor Pharma and until his appointment at Akari was the managing partner of Sund Capital, a Nordic healthcare investment fund.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK